Alicia Morgans, MD, MPH Discusses the Importance of Patient Support Networks During the COVID-19 Pandemic

Video

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk about the important role that patient support networks play for those with cancer and the challenge of separating patients from their loved ones during the COVID-19 pandemic.

At the 2021 European Society of Medical Oncology Congress, CancerNetwork® spoke with Alicia Morgans, MD, MPH, director of the survivorship program at Dana-Farber Cancer Institute, about the importance of patient support networks for those with cancer during the COVID-19 pandemic. Morgans highlighted the challenges in separating patients from their loved ones when entering the clinic room, as well as the strength and resilient she saw from her patients during the pandemic.

Transcript:

The pandemic has truly turned the whole world upside down. Whether you work in cancer care, whether you’re a parent, whether you have a job that you now can’t go to regularly, all of us have experienced and been touched by the events from the last year.

Specifically, when it comes to cancer care, I think that it has shown me how incredibly important patient support networks are to them. When we had periods of time in our clinics where we couldn’t let family members come into the clinic room and patients had to be on their own, it was truly heart wrenching. I’m glad that we as healthcare providers are able now to be vaccinated [and can] let family members support the patients that they care about. I think that I never want to learn the lesson again where I have to separate people from their support. I’m just so amazed at how much the people around [those] with cancer do to get people through these experiences. I’m just touched, and I’m happy that we hopefully will not have to do that again.

Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Related Content